The Medical Letter on Drugs and Therapeutics
A Rivastigmine Patch for Dementia
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

Cholinesterase inhibitors are now used routinely in patients with dementia.1 Rivastigmine transdermal system (Exelon Patch – Novartis), a patch formulation of the cholinesterase inhibitor rivastigmine tartrate, has been approved by the FDA for treatment of mild to moderate dementia associated with Alzheimer’s or Parkinson’s disease. An oral formulation of rivastigmine tartrate has been available in the US since 2000,2 but gastrointestinal adverse effects possibly related to rapidly rising serum concentrations have limited its use.3

MECHANISM OF ACTION — Cognitive deficits in Alzheimer’s disease have been associated with degeneration of cholinergic neurons in the brain. Rivastigmine, a noncompetitive cholinesterase inhibitor with good penetration into the central nervous system, increases ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: A Rivastigmine Patch for Dementia
Article code: 1282a
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian